Date Filed | Type | Description |
08/09/2023 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 75,000 rights
@ $0 |
|
08/09/2023 |
4
| Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 223,500 rights
@ $0 |
|
08/09/2023 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 75,000 rights
@ $0 |
|
08/09/2023 |
4
| Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 50,000 rights
@ $0 |
|
08/09/2023 |
4
| Kraus Carl N (Chief Medical Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 150,000 shares
@ $0 |
|
08/09/2023 |
4
| Wargacki Stephen (SVP, Research & Development) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 67,500 rights
@ $0 |
|
08/09/2023 |
4
| TOTH A ERNEST JR (SVP, CFO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 70,000 rights
@ $0 |
|
08/09/2023 |
4
| Schobel Alexander Mark (Chief Innovation/Tech Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 50,000 rights
@ $0 |
|
08/09/2023 |
4
| Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 55,000 rights
@ $0 |
|
06/30/2023 |
3
| Kraus Carl N (CHIEF MEDICAL OFFICER) has filed a Form 3 on Aquestive Therapeutics, Inc. |
05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2023 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 75,000 rights
@ $0 |
|
05/05/2023 |
4
| Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 223,500 rights
@ $0 |
|
05/05/2023 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 75,000 rights
@ $0 |
|
05/05/2023 |
4
| Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 55,000 rights
@ $0 |
|
05/05/2023 |
4
| Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 50,000 rights
@ $0 |
|
03/09/2023 |
4
| Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 100,000 shares
@ $0 |
|
03/09/2023 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 150,000 shares
@ $0 |
|
03/09/2023 |
4
| Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 110,000 shares
@ $0 |
|
03/09/2023 |
4
| Schobel Alexander Mark (Chief Innovation/Tech Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 100,000 shares
@ $0 |
|
03/09/2023 |
4
| Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 447,000 shares
@ $0 |
|
03/09/2023 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 150,000 shares
@ $0 |
|
03/09/2023 |
4
| Wargacki Stephen (SVP, Research & Development) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 135,000 shares
@ $0 |
|
03/09/2023 |
4
| TOTH A ERNEST JR (SVP, CFO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 140,000 shares
@ $0 |
|
01/11/2023 |
3
| Jung Cassie (SVP, Operations) has filed a Form 3 on Aquestive Therapeutics, Inc. |
01/11/2023 |
3
| Wargacki Stephen (SVP, Research & Development) has filed a Form 3 on Aquestive Therapeutics, Inc. |
11/08/2022 |
4
| Boyd Peter E. (SVP-Bus. Process & Info. Tech.) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.875, valued at
$21.9k
|
|
11/08/2022 |
4
| BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $0.875, valued at
$35k
|
|
11/08/2022 |
4
| Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $0.875, valued at
$35k
|
|
11/08/2022 |
4
| Schobel Alexander Mark (Chief Innovation/Tech Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $0.875, valued at
$35k
|
|
11/08/2022 |
4
| TOTH A ERNEST JR (SVP, CFO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $0.875, valued at
$35k
|
|
09/08/2022 |
4
| Truitt Kenneth (Chief Medical Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $1.25, valued at
$125k
|
|
|